Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.
종목 코드 AIMD
회사 이름Ainos Inc
상장일Aug 08, 1996
CEOMr. Chun-Hsien Tsai
직원 수44
유형Ordinary Share
회계 연도 종료Aug 08
주소8880 Rio San Diego Drive, Ste. 800
도시SAN DIEGO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호92108
전화18588692986
웹사이트https://www.ainos.com/
종목 코드 AIMD
상장일Aug 08, 1996
CEOMr. Chun-Hsien Tsai
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음